Julian Adams is a businessperson who has been the head of 6 different companies. He holds the position of Chairman at Elicio Therapeutics, Inc. and Chairman of Elicio Therapeutics, Inc. (Old) (a subsidiary of Elicio Therapeutics, Inc.) and Chief Executive Officer & Director at Gamida Cell, Inc. Dr. Adams is also on the board of Gamida Cell Ltd. (former Chief Executive Officer & Director) and Princess Margaret Cancer Foundation.
In the past Dr. Adams was President & Chief Science Officer at Clal Biotechnology Industries Ltd. and President & Chief Science Officer at Clal Biotechnology Industries Ltd. (Venture Capital) (a subsidiary of Clal Biotechnology Industries Ltd.), President-Research & Development at Infinity Pharmaceuticals, Inc. and President at Infinity Discovery, Inc. (a subsidiary of Infinity Pharmaceuticals, Inc.), Medicinal Chemist at Merck & Co., Inc., Advisor at Limulus Management Co. LLC, Senior Vice President-Research & Development at LeukoSite, Inc., Director, Executive VP-Research & Development at ProScript, Inc., Senior Vice President-Drug Discovery & Development at Millennium Pharmaceuticals, Inc. and Director-Medicinal Chemistry at Boehringer Ingelheim Corp.
He received an undergraduate degree from McGill University and a doctorate from Massachusetts Institute of Technology.
|10/19/2023||28,300||Award at $0 per share.||0|
|02/08/2023||28,300||Award at $0 per share.||0|
|11/18/2022||2,000||Award at $0 per share.||0|
|07/27/2022||68,800||Award at $0 per share.||0|
|07/27/2022||48,500||Award at $0 per share.||0|